Literature DB >> 7996011

Failure to detect a Plasmodium vivax-like malaria parasite in globally collected blood samples.

R Gopinath1, C Wongsrichanalai, C Cordón-Rosales, L Mirabelli, D Kyle, K C Kain.   

Abstract

Two variants of the circumsporozoite (CS) protein of Plasmodium vivax (VK210 and VK247) have been identified. Recently, a putative third CS variant of P. vivax, referred to as causing P. vivax-like malaria, has been reported from Papua New Guinea. The objective of this study was to confirm and extend findings on the global distribution of the P. vivax-like parasite. Blood samples were obtained from 126 untreated patients with P. vivax infection acquired in Central America, South America, Africa, Southeast Asia, and the Indian subcontinent. The P. vivax CS gene was amplified by polymerase chain reaction and hybridized with probes specific for the VK210, VK247, and P. vivax-like CS variants. All samples were positive for VK210, VK247, or both. No sample was positive for P. vivax-like DNA. Therefore, the existence of a third variant of P. vivax cannot be confirmed in the geographic areas studied.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7996011     DOI: 10.1093/infdis/170.6.1630

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

1.  Differential susceptibilities of Anopheles albimanus and Anopheles pseudopunctipennis to infections with coindigenous Plasmodium vivax variants VK210 and VK247 in southern Mexico.

Authors:  L Gonzalez-Ceron; M H Rodriguez; J C Nettel; C Villarreal; K C Kain; J E Hernandez
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

Review 2.  Host Cell Tropism and Adaptation of Blood-Stage Malaria Parasites: Challenges for Malaria Elimination.

Authors:  Caeul Lim; Selasi Dankwa; Aditya S Paul; Manoj T Duraisingh
Journal:  Cold Spring Harb Perspect Med       Date:  2017-11-01       Impact factor: 6.915

3.  Immunological evaluation of two novel engineered Plasmodium vivax circumsporozoite proteins formulated with different human-compatible vaccine adjuvants in C57BL/6 mice.

Authors:  Samaneh H Shabani; Sedigheh Zakeri; Yousef Mortazavi; Akram A Mehrizi
Journal:  Med Microbiol Immunol       Date:  2019-04-25       Impact factor: 3.402

4.  Immunogenicity of recombinant proteins consisting of Plasmodium vivax circumsporozoite protein allelic variant-derived epitopes fused with Salmonella enterica Serovar Typhimurium flagellin.

Authors:  Monica Teixeira Andrade Leal; Ariane Guglielmi Ariza Camacho; Laís Helena Teixeira; Daniel Youssef Bargieri; Irene Silva Soares; Cibele Aparecida Tararam; Mauricio M Rodrigues
Journal:  Clin Vaccine Immunol       Date:  2013-07-17

5.  Immunogenicity of a prime-boost vaccine containing the circumsporozoite proteins of Plasmodium vivax in rodents.

Authors:  Lais H Teixeira; Cibele A Tararam; Marcio O Lasaro; Ariane G A Camacho; Jonatan Ersching; Monica T Leal; Sócrates Herrera; Oscar Bruna-Romero; Irene S Soares; Ruth S Nussenzweig; Hildegund C J Ertl; Victor Nussenzweig; Mauricio M Rodrigues
Journal:  Infect Immun       Date:  2013-12-09       Impact factor: 3.441

6.  Serological responses to a soluble recombinant chimeric Plasmodium vivax circumsporozoite protein in VK210 and VK247 population.

Authors:  Yang Cheng; Daisuke Ito; Jetsumon Sattabongkot; Chae Seung Lim; Deok-Hoon Kong; Kwon-Soo Ha; Bo Wang; Takafumi Tsuboi; Eun-Taek Han
Journal:  Malar J       Date:  2013-09-14       Impact factor: 2.979

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.